Twenty-two years ago California built a biomedical research institution. Six years ago it renewed and strengthened it. Proposition 38 builds something different.

A NeuroSaeculum assessment

Table of Contents

Introduction

Before anything else

The need is real. Federal science funding is being cut in ways the research community describes as existential. California’s universities and research institutes are absorbing serious damage. Immunology and immunotherapy are among the most promising frontiers in medicine, and the diseases Proposition 38 targets — cancer, heart disease, Alzheimer’s — take people we love.

This assessment accepts all of that. It does not argue that medical research is a poor investment, that immunology is overhyped, or that California should sit still while Washington dismantles the NIH.

It asks a different question.

The two questions

Any public institution — a water district, a pension board, a research institute — can be evaluated by asking two things:

Can it be seen into?

Can it be repaired?

An institution that fails both is not necessarily corrupt, badly run, or doomed. It is an institution in which, if things go wrong, they are more likely to go wrong quietly and to stay wrong.

California has answered those two questions before, in this exact policy domain, twice.

In 2004, Proposition 71 created the California Institute for Regenerative Medicine (CIRM) — a multibillion-dollar research institution subject to the Public Records Act, the Bagley-Keene Open Meeting Act, and the Political Reform Act.

In 2020, Proposition 14 renewed it and strengthened it: a performance audit every three years, double the public meetings, every board member’s recusals published, patient advocates seated on the scientific peer-review panels, a mechanism to remove a board member, and a tighter cap on how much any single recipient could receive.

Proposition 38 borrows language from both. And on the two questions, it goes the other way.

This assessment does not tell you how to vote. It tells you what is in the text, how it compares to what California built the last two times, what we are confident about, what we are not, and what should be answered before any organization puts its name on this.

Executive Summary

What Proposition 38 would do

Authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research. The Legislative Analyst estimates roughly $500 million a year for 25 years — about $12.5 billion in total General Fund payments, though the state could recoup some if the research generates revenue.

The money splits in half: $4.2 billion to one private nonprofit institute affiliated with a UC campus, and $4.2 billion to a grant program restricted to institutions holding a seat on the council that awards the grants. At least half must go to cancer, heart disease, and Alzheimer’s research. Resulting drugs are to be sold to Californians at 20% below the national average price.

Written and largely funded by Dr. Gary K. Michelson, who contributed $6 million of the $11 million raised. As of publication no opposition committee has registered, though former NIH associate director Robert Kaplan publicly opposes the measure, and a July 31, 2026 CalMatters investigation examined its single-institute design.

The six findings

Finding 1 — The recipient of $4.2 billion is exempt from California’s transparency and ethics laws.

Observation. §130363(a): the institute “shall not be deemed a public agency for any purpose under state law” — naming the Public Records Act, the Bagley-Keene Open Meeting Act, and the Political Reform Act (financial disclosure and conflict of interest).

Why it matters. No reporter, legislator, or member of the public could file a records request against it. Its board could meet entirely in private. Its directors would not disclose their financial interests.

Comparison. CIRM has been subject to all three since 2004. Proposition 14 reaffirmed it in 2020 — and added a requirement that every board member’s votes and recusals be published in the minutes.

Finding 2 — The Legislature could never change the allocation.

Observation. Section 7 of the initiative permits amendment by two-thirds of both houses plus the Governor — except for “the allocation and disbursement of bond proceeds.” That is permanently locked, at any vote threshold.

Why it matters. There is a serious argument for voting yes that ends “take the money now and fix the governance later.” Section 7 makes that unavailable. Not difficult. Unavailable.

Comparison. Both CIRM measures allow the Legislature to amend the allocation at a 70% supermajority. That path is real and has been used.

Finding 3 — Half the bond goes to one recipient. California’s rule was one percent.

Observation. §130352(b)(1) directs 50% of the bond to a single institute, selected under criteria anchored to dates already in the past, with no application, no scoring, and no competitive process.

Why it matters. No institution can newly qualify. The eligible list was fixed before voters knew the measure existed — and reporting has since confirmed that only the sponsor’s own institute appears to qualify.

Comparison. Proposition 71 capped any single grantee at 2% of the bond per year. Proposition 14 tightened it to 1%.

Finding 4 — There is no performance audit.

Observation. §130361 requires annual financial audits. There is no scientific audit, no performance audit, no clawback, and no remedy for underperformance.

Why it matters. Who checks whether the program is actually working — not merely whether its books balance?

Comparison. Proposition 14 added a triennial performance audit, potentially conducted by the Bureau of State Audits, examining whether the institution achieves “economy, efficiency, and effectiveness,” including a review of its grant and contract procedures and its intellectual-property practices.

Finding 5 — Patients are not in the room.

Observation. The council that awards the competitive $4.2 billion is seven UC chancellor appointees, who then appoint 10–15 more from the institutions eligible to receive the grants. Peer review is optional (§130356(c)(1): the council “may” establish panels).

Why it matters. The body deciding where $4.2 billion of research money goes contains no patients, no public members, and no one appointed by an elected official — and it appoints most of itself.

Comparison. Proposition 71 seated ten patient and disease-advocacy representatives on the governing board, appointed by the Governor, Lieutenant Governor, Treasurer, Controller, Speaker, and Senate President pro Tem. Proposition 14 raised it to twelve and required patient advocates on every scientific peer-review panel.

Finding 6 — One private institute controls commercialization of all $8.4 billion.

Observation. §130358(e)(2): the selected institute is the “clearinghouse and approval center for all agreements” to license or commercialize any discovery funded by the measure — including from the competitive half. Every licensing agreement from every grantee must be submitted to it before signing. §130357(d) and (e) give it, and UCLA, a right to participate in the research it reviews.

Why it matters. A single private entity — the one that is not a public agency for any purpose under state law — sits as gatekeeper over the commercialization of the entire bond.

Comparison. Under CIRM, intellectual-property policy is set by a public board in public meetings, and its IP practices are subject to the performance audit.

What we do not claim

We do not allege wrongdoing by anyone. Not by Dr. Michelson, not by UCLA, not by any researcher or institution. Every finding survives the assumption that everyone involved is acting in complete good faith. That is the point. Governance structure matters most when everyone is honorable, because it is what protects an institution from people not yet involved in it.

We do not claim the author-funder relationship is unusual. It isn’t. Robert Klein wrote Proposition 71, chaired the institution it created, then wrote Proposition 14 and funded most of its campaign. Structurally, that is the same pattern.

The difference is what each author built. Klein built an institution that answers records requests, meets in public, publishes its recusals, seats patient advocates, submits to performance audits, caps concentration, and can be amended by the Legislature. The conflict was disclosed — and then constrained by architecture.

The Lineage: 2004 → 2020 → 2026

Every row is drawn from the operative text of the three measures. This is the assessment’s evidentiary core.

Cluster 1 — Can the public see what is happening?

	Prop 71 (2004)	Prop 14 (2020)	Prop 38 (2026)
Public Records Act	Applies to the institute	Applies	Exempt by name
Open Meeting Act	Applies; 2 public meetings/yr; grants awarded in public	Applies; 4 public meetings/yr	Exempt by name
Financial disclosure (Form 700)	Required	Required	Exempt by name
Votes and recusals published	—	Required in all minutes	No public meetings
Financial audit	Annual, reviewed by Controller	Annual	Annual
Performance audit	—	Every 3 years — economy, efficiency, effectiveness; grants, contracts, IP practices	None

The confidentiality objection

The obvious defense of §130363(a) is that biomedical research must protect trade secrets, prepublication data, and licensing positions. That is a serious argument — and California addressed it twice, with a narrower instrument.

Both CIRM measures permit closed sessions and records exemptions specifically for “confidential intellectual property or work product,” “prepublication, confidential scientific research or data,” and patient privacy. CIRM licenses biomedical IP at scale, recruits scientists, and handles unpublished data — as a public agency, for twenty-two years.

Proposition 38 did not take the narrow instrument. It took a blanket exemption — one that reaches things confidentiality cannot explain. Trade secrets do not explain why the directors of a $4.2 billion recipient shouldn’t disclose their financial interests. Donor privacy does not explain why board meetings must be closed.

We invite the proponents to identify a confidentiality interest that the CIRM model cannot address. We have not found one.

Cluster 2 — Who participates, and who decides?

	Prop 71 (2004)	Prop 14 (2020)	Prop 38 (2026)
Patient / disease-advocacy reps on the governing body	10	12	0
Patient advocates in scientific peer review	—	Required on every expert review panel	Peer review is optional
Appointed by Governor, Lt. Gov., Treasurer, Controller	4 + 8 advocacy seats	More	0
Appointed by the Speaker / Senate pro Tem	2	2	0
Members the body appoints itself	0	0	10–15 of 17–22
Mechanism to remove a member	—	Yes — 60% of a quorum	None
Competitive bidding on institute contracts	UC standard	UC standard	None

One thing Proposition 38 did keep

§130362 retains a Citizens’ Financial Accountability Oversight Committee, with members appointed by the State Auditor, the Treasurer, the Senate President pro Tem, and the Speaker, chaired by the Controller. That is real, and it is copied from the CIRM model.

But note precisely what it does. It reviews financial audits and issues recommendations. It has no authority over the institute’s operations and no role in any grant decision. So the accurate statement is not “Prop 38 has no public appointees.” It is:

The body that awards the grants has no public members, no elected-official appointees, and no patient advocates. The only body with public appointees is advisory, financial-only, and has no reach into how the money is spent.

Cluster 3 — Can funding be dispersed, and can mistakes be corrected?

	Prop 71 (2004)	Prop 14 (2020)	Prop 38 (2026)
Maximum to any single recipient	2% of the bond per year	1% of the bond per year	50% of the bond, by statute
May the Legislature amend the allocation?	Yes — 70% of both houses + Governor, after 3 years, with 14 days’ public notice	Yes — 70% of both houses + Governor	No. Never. At any threshold.
Who may apply for grants?	Competitive; open	Competitive; open	Only institutions seated on the awarding council
Administrative budget for oversight	~6%	~7.5%	2%, shared across four bodies
Indirect cost cap on grants	25%	25%	20%

On the amendment lock

Proposition 38’s drafters knew how to write a high-but-finite bar. They wrote one and applied it to everything else in the measure — two-thirds of both houses, the Governor’s signature, and a requirement that any change “further the purposes of this act.” That already defeats casual raiding.

Then they removed allocation from it entirely.

So the tradeoff is not stability versus flexibility. Stability was already purchased. What the permanent lock adds is immunity from correction.

On concentration

Every eligibility requirement for the $4.2 billion institute is anchored to a date already in the past: a nonprofit already in existence as of January 1, 2025; a UC affiliation agreement signed on or before January 1, 2025; bylaws adopted on or before January 1, 2025; a 200,000-square-foot site held as of January 1, 2026; $250 million in philanthropic funding identified in that 2025 agreement; and $50 million secured for a rapid vaccine program and $50 million for a microbiome program.

No institution can newly qualify. You cannot retroactively found yourself, sign an agreement, or raise $250 million.

There is no application, no scoring, and no competitive selection — §130353(b)(1) directs the Department of Public Health to “select and enter into a funding agreement… within 90 days.” And if no one qualifies, §130353(b)(2) directs the Department to loosen the criteria until someone does. That guarantees disbursement. It never widens the field when someone already qualifies.

Whose profile is this? In August 2024, UCLA announced a $120 million commitment from Gary and Alya Michelson to launch the California Institute for Immunology and Immunotherapy. Per UCLA’s own announcement, $100 million of it established two research entities inside the institute, each funded with $50 million — one for rapid vaccine development, one for microbiome research. Dr. Michelson is the institute’s co-founder and board chair.

We are not going to characterize why §130353(a)(7) names that specific pair of programs at those specific amounts. We will say that we cannot construct another explanation, and we invite anyone who can to offer one.

Update (August 2026): This has now been reported out. A July 31, 2026 CalMatters investigation found that a UCLA spokesperson confirmed only the California Institute for Immunology and Immunotherapy — the institute Michelson co-founded and chairs — could satisfy the criteria among UCLA-affiliated nonprofits, and that UCLA is the only UC campus meeting the 3.5-million-outpatient-visit threshold in the UC system’s own fiscal audit. Asked directly to name any institute that might qualify, the Yes on 38 campaign said it “can’t speak to the specific institutes that may or may not qualify across California.” A Cal State Fullerton ballot-process scholar quoted in the same report called the language “very clearly designed to support a specific nonprofit.”

We had labeled the sole-source reading an inference and invited anyone to name a competing institute. No one has. But no other finding in this assessment ever depended on it: whoever is selected is exempt from the Public Records Act, holds approval rights over the other half of the money, and cannot be restructured by the Legislature.

The pricing promise

The 20% discount is the measure’s principal promise to ordinary Californians. What §130358(b) actually provides:

In the first twelve months there is no discount at all. California simply can’t be charged more than anywhere else. The 20% begins in month thirteen.
The benchmark is the national average price “calculated by excluding California.”
There is no penalty, no clawback, no enforcement authority, and no remedy specified anywhere in the statute.

The enforcement gap is a matter of text and it is clear: the Department of Public Health would police pharmaceutical pricing for twenty-five years from an administrative budget capped at 2% and shared with three other bodies.

Compare Proposition 14. Royalty revenues go into an interest-bearing General Fund account specifically appropriated to offset the cost of treatments for California patients who cannot afford them, with detailed statutory revenue-sharing formulas. Whatever its flaws, it names a beneficiary and a funding stream.

One further concern, held with low confidence and flagged for rebuttal: because the benchmark excludes California, the formula may create an incentive for manufacturers to raise prices in the other forty-nine states — lifting the benchmark and delivering Californians a 20% discount off a number the manufacturer chose. We are not health economists. This is the weakest claim in this assessment, and we will withdraw it if a qualified expert knocks it down. The enforcement gap survives either way.

The case for voting yes, taken seriously

1. Federal science funding is being destroyed. — True, and urgent. The damage is real and severe. Anyone treating this as pretext is not being serious.

2. There is no alternative on the ballot. — True, and the reason matters. SB 895 — the UC- and UAW-sponsored $12 billion research bond, developed through the legislative process — passed the Senate 29–9 and was then placed on the suspense file in Assembly Appropriations and never reached the floor before the June 25 deadline.

It did not die on the merits. Politico California reported that Governor Newsom and legislative leaders had backed Assemblymember Buffy Wicks’s $11.25 billion affordable housing bond, and that there was only so much lawmakers were willing to put on a single ballot. Wicks — who chairs Appropriations — put it plainly: “I’m not opposed to the science bond, but there’s only so much bond capacity.”

So the vehicle California’s own Democratic leadership declined to advance is not on the ballot. The one that bought its way past the Legislature with paid signature gathering is. A citizens’ initiative cannot be crowded out.

Prop 38 is therefore the only research money on any 2026 ballot. “Eight billion beats zero” is a real argument — and it is real precisely because the deliberative path was closed.

3. Private money comes with it. — True. $250 million in identified philanthropic funding is leverage the state would not otherwise get.

4. Concentration can beat diffusion. — Partly true. The measure’s own statement of purpose (Section 3(f)) says as much. But concentration does not require exemption from the Public Records Act, does not require approval rights over other people’s grants, does not require eliminating the performance audit, and does not require locking out the Legislature permanently. Those are separable choices.

5. CIRM is the precedent, and CIRM worked. — True, and it cuts both ways. Klein wrote Prop 71 and chaired the institution it created, and CIRM still produced serious science: over 1,000 funded projects, 2,500 peer-reviewed discoveries, 70-plus clinical trials, two FDA-approved drugs.

The twenty-two-year record demonstrates that California has supported large-scale, confidential biomedical research while retaining public-records access, open meetings, patient participation, performance auditing, concentration limits, and legislative repair authority. Proposition 38’s departures therefore require a specific justification. They cannot be treated as self-evidently necessary to biomedical research — because twice, they weren’t.

6. “Pass it now, fix it later.” — This one fails. Section 7 forecloses it.

The question nobody is asking

California already owns a functioning, audited, publicly accountable, twenty-two-year-old biomedical research funding institution with real experience in grant-making, peer review, intellectual property, and commercialization.

It is running out of money.

Why does Proposition 38 create a parallel, less publicly accountable structure rather than use or adapt California’s existing biomedical research institution?

Why not expand its mission to immunology? Create a specialized division? Borrow its governance model? Use its grant, audit, commercialization, and public-accountability machinery?

The proponents may have a compelling answer. They should be asked to give it.

How it could be built better

Every change below preserves the science, the $8.4 billion, the bond mechanism, the disease priorities, the concentration in a flagship institute, and the philanthropic money. None requires shrinking the measure’s ambition. Each is severable from the others.

	Change	What it costs the proponents
1	Apply the Public Records Act, Bagley-Keene, and the Political Reform Act to the institute — with the CIRM measures’ narrow carve-outs for confidential IP, prepublication data, and patient privacy. The language exists and has worked for twenty-two years.	Nothing CIRM hasn’t already absorbed.
2	Replace the Section 7 permanent lock with the CIRM model: allocation amendable at a 70% supermajority.	The guarantee that the split can never be revisited — even if it fails.
3	Add a triennial performance audit, as Proposition 14 did.	Scrutiny of whether the program works, not just whether the books balance.
4	Make grant eligibility criteria-based, not membership-based. Any qualified California nonprofit or public institution may apply. Keep the council as reviewers; remove it as the gate.	Guaranteed seats for ~22 institutions.
5	Put patients and the public back on the grant body. Constitutional-officer appointees. Legislative appointees. Patient advocates — Prop 71 seated ten; Prop 14 seated twelve and put them on the peer-review panels.	A self-appointing majority.
6	Move the licensing clearinghouse out of the largest grant recipient into an independent body or the Department.	The institute’s approval authority over its peers.
7	Give the 20% discount a remedy — a penalty, a clawback, an enforcement authority — and fund enforcement above the 2% cap.	Nothing, unless the point was that it not be enforced.

The test we would apply to any measure: Can the stated goal be achieved without this structural feature? Where the answer is yes, the feature is doing something other than serving the stated goal. What that something is, this assessment does not speculate.

What we conclude

Nothing about a vote.

These structural characteristics materially affect the governance profile of Proposition 38, and they should be weighed alongside its scientific objectives, its fiscal cost, and the genuine urgency of the need it addresses.

An organization considering an endorsement should have answers to the following first:

Why is the recipient of $4.2 billion exempt from the Public Records Act, the Bagley-Keene Open Meeting Act, and the Political Reform Act, when CIRM is subject to all three?
Why can the Legislature never amend the allocation, when it can amend both CIRM measures’ allocations at 70%?
Why does half the bond go to one recipient, when California’s rule in 2020 was 1% per year?
Why is there no performance audit, when Proposition 14 added one in 2020?
Why are there no patient advocates and no public members on the body that awards the grants?
Why does the 20% discount have no penalty, no enforcement authority, and no remedy?
Why not use or adapt CIRM?
Where does the University of California stand?

An organization may hear the answers, weigh them against the collapse of federal science funding and the absence of any alternative on the ballot, and endorse anyway. That is a coherent position, and this assessment does not argue against it.

What it argues is that the position must be reached knowingly. A judgment made with §130363(a) and Section 7 on the table can be defended in public in October. A judgment made because immunology is worth funding cannot.

Corrections

What we got wrong, and how we found out. Published, not buried.

These are corrections made during this assessment’s development, before publication. None appeared in the published version. They are recorded here so readers can see where the analysis was wrong and how it was found.

We reported the philanthropic threshold as $25 million. That came from a secondary summary. The statute says $250 million. We had repeated a figure without checking it against the text.
We framed the 20% indirect-cost cap as an assault on UC. It isn’t novel — both CIRM measures capped indirect costs at 25% in nearly identical language. Prop 38 tightens it by five points. Worth noting; our framing overstated it. Withdrawn.
We said Prop 38’s conflict-of-interest rules were weaker than CIRM’s. They are verbatim identical — copied from Prop 71. The real difference is that CIRM applies the Political Reform Act to both the board and the institute, while Prop 38 exempts the institute entirely. Corrected to the narrower, accurate claim.
We said Prop 38 has no public appointees. It retains the Citizens’ Financial Accountability Oversight Committee, with appointees from the State Auditor, Treasurer, Speaker, and Senate pro Tem. That committee is advisory and financial-only — but it exists, and the original claim was too broad.
We nearly published without reading Proposition 14. We had assumed the lineage ran 2004 → 2026 and that the 2020 measure was context. It is the single most important comparison in this document, and every major finding is stronger because of it.

Assessment Development

A standing record of how the analysis moved. Included so that readers can audit the reasoning, not just the conclusion.

How this was produced. This assessment was developed using a multi-model adversarial review process — analyses drafted, then attacked and revised across independent AI systems, with all statutory claims verified against primary texts. Several of the corrections above were surfaced by that process. All findings were checked against the operative language of the three initiatives, which are linked in Sources. Errors that remain are the author’s.

Initial hypothesis. Proposition 38 is a large biomedical research bond with a possible conflict of interest attached to its author. The central question is whether the conflict disqualifies it.

What changed. Reading the statute reframed the question entirely. The conflict is real but is not the finding. The finding is architectural: the measure exempts its principal recipient from public-accountability law and forecloses legislative repair. Those are facts in the text, not inferences about intent, and they survive the assumption that every party is acting in good faith.

What changed again. Reading Proposition 71 revealed that Prop 38’s conflict-of-interest provisions are copied from it — while the accountability framework those provisions were carved out of is absent. Reading Proposition 14 revealed that California had strengthened that framework as recently as 2020. The comparison shifted from “Prop 38 differs from a 2004 measure” to “Prop 38 reverses a twenty-two-year trajectory.”

What was falsified. Four claims, listed above. In each case the correction narrowed and strengthened the finding.

What was tested and survived. Four of six arguments for voting yes. The confidentiality defense of §130363(a) was steelmanned and does not hold, because California addressed the same interest twice with a narrower instrument. The author-funder objection was conceded outright: it is the California pattern, and it is not the finding.

What remains open.

Does only one institution qualify under §130353(a)? A UCLA spokesperson told CalMatters (July 31, 2026) that only CIII qualifies among UCLA-affiliated nonprofits, and the UC fiscal audit shows only UCLA meets the outpatient threshold. That is strong corroboration but not a statewide proof — an independent institute affiliated with UCLA is the remaining theoretical path. Largely resolved; not formally closed.
Can the drug-pricing benchmark be gamed? We think so; we are not qualified to be sure. Needs a health economist.
Does §130358(b) survive interstate-commerce review? Needs a lawyer.
Where does the University of California stand? UC sponsored SB 895 and has taken no public position on Prop 38. But a UCLA spokesperson confirmed to CalMatters (July 31, 2026) that only the Michelson-chaired institute qualifies among UCLA-affiliated nonprofits — and four senior UCLA officials, including the chancellor, sit on that institute’s board. UCLA is not neutral on this measure; it is structurally embedded in it. A formal position from the UC system would still be informative.
Where does UAW 4811 stand? They co-sponsored SB 895 and represent sixty thousand UC academic workers.

What would falsify this assessment.

A qualifying institute emerges that is not the Michelson-chaired CIII — which, after the CalMatters reporting, would now require rebutting UCLA’s own spokesperson. (Even then, the other five findings survive.)
The Department of Public Health has selection discretion we have missed in the text.
A confidentiality interest exists that the CIRM model demonstrably cannot address.
The drug-pricing benchmark cannot be gamed. (We withdraw that claim; the enforcement gap survives.)
The University of California affirmatively endorses the measure. We would weight that heavily.

Method

Evidence typing. Every claim is one of four kinds: statutory fact (in the operative text, section-cited); external fact (Secretary of State, Attorney General, Legislative Analyst, campaign filings, institutional announcements, the CIRM measures’ texts); inference (reasoning from those, always labeled); or open (unverified, and listed as such). Findings 1 through 6 are almost entirely statutory fact. The drug-pricing benchmark is the only significant unresolved inference. The exclusivity of the eligible institute, originally flagged as inference, has since been substantially corroborated by reporting (see “On concentration”).

Three layers, kept separate. Institutional analysis fails when observation, structural implication, and risk projection collapse into a single claim.

Layer	Example
Observation	The institute is exempt from the Public Records Act.
Structural implication	The public has fewer tools to monitor $4.2 billion than under CIRM.
Institutional risk	If something goes wrong, it becomes more likely to be found late, or not at all.

The third layer is probabilistic, never deterministic. Reduced transparency does not cause failure. It removes the tools that surface failure. Those are different claims, and we do not conflate them.

Sources

Proposition 38 (2026)

Initiative 25-0026A1 — full text as amended December 8, 2025 (Office of the Attorney General)
Legislative Analyst’s Office fiscal analysis, A.G. File No. 25-0026, Amendment #1
Secretary of State: “Proposed Initiative Enters Circulation,” January 2, 2026 — contains the AG’s official title and summary
Secretary of State: Official Top Funders (February 25, 2026)
Ballotpedia: California Proposition 38 (2026) — campaign finance totals and qualification timeline

Proposition 71 (2004)

Full text — California Stem Cell Research and Cures Act (via CIRM)
§125290.20 (ICOC membership) · §125290.30 (public and financial accountability — Bagley-Keene, Public Records Act, Political Reform Act, closed-session carve-outs) · §125290.60 (competitive grant evaluation) · §125290.70 (allocation; 2% single-grantee cap; 25% indirect cost cap) · SEC. 8 (amendment — 70%, three-year wait, fourteen-day public notice)

Proposition 14 (2020)

Full text — California Stem Cell Research, Treatments, and Cures Initiative (via CIRM)
§125290.20 (35 members; nurses; mental-health advocates; removal mechanism) · §125290.30 (triennial performance audit; four public meetings; recusal disclosure in minutes; royalty account for patient affordability) · §125290.60 (patient advocates required on peer-review panels) · §125290.70.5 (1% single-grantee cap; 25% indirect cost cap) · §125290.40(q) (National Academy of Sciences conflict standards) · SEC. 26 (amendment — 70%)

The institute

SB 895 — the alternative that didn’t make the ballot

Reporting

Mikhail Zinshteyn, “Is this proposition a $4 billion giveaway to a billionaire-backed LA research center?” CalMatters, July 31, 2026 — UCLA spokesperson confirmation that only CIII qualifies; UC fiscal audit on outpatient thresholds; Yes on 38 campaign response; Robert Kaplan’s opposition; Prof. Sarah Hill (CSU Fullerton) on the ballot language.

Published by NeuroSaeculum. An institutional assessment — not legal advice, and not a voting recommendation. The primary texts are the only authority that matters; readers are urged to consult them.

Proposition 38: An Institutional Assessment